Denali Therapeutics Inc. (DNLI)
|52 Week Range||20.24-39.43|
|1y Target Est||-|
|DCF Unlevered||DNLI DCF ->|
|DCF Levered||DNLI LDCF ->|
|Debt / Equity||40.08%||Neutral|
Upgrades & Downgrades
Latest DNLI news
Why Is Denali Therapeutics Inc. (DNLI) Down 16% Since Last Earnings Report?
29 March 2023
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?
Denali (DNLI) Q4 Earnings Beat Estimates, Pipeline in Focus
28 February 2023
Denali (DNLI) reports better-than-expected results for the fourth quarter and full-year 2022, as it beats both earnings and revenue estimates.
Denali Therapeutics Inc. (DNLI) Reports Q4 Loss, Tops Revenue Estimates
27 February 2023
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 3.85% and 28.09%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st...
3 More Mid-Cap Biotechs The Street Sees Doubling
22 February 2023
Over the next 10 to 20 years, some of healthcare's most impactful innovations will come from biotechnology companies. They'll produce medicines based on living organisms that will save and improve the...
Denali Therapeutics Inc. (DNLI) Surges 5.8%: Is This an Indication of Further Gains?
3 February 2023
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further pri...
Denali: Need Patient Data To Justify That High Valuation
16 January 2023
Denali Therapeutics Inc. has major partnerships and an active set of programs. They are flush with cash.
Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus
4 November 2022
Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates
3 November 2022
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -1.20% and 64.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the ...
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
2 November 2022
The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >